Six years before the pandemic, fledgling Cambridge biotech Moderna was searching for a way to get its revolutionary RNA technology to work in humans. One of the biggest problems was figuring out how ...

BERLIN--(BUSINESS WIRE)--Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular ...

Michael Mitchell, an associate professor of bioengineering at the University, is developing novel lipid nanoparticles that can deliver mRNA inside human cells, which could pave the way for therapies ...

Under Leshem's leadership, ViVac will accelerate its preclinical oncology pipeline, which includes programs in liver, ovarian ...

Certest Pharma specializes in advanced lipid nanoparticle technology, focusing on the development of effective and targeted LNPs for next-generation medicines. Certest’s licensable technology includes ...

The COVID-19 pandemic has necessitated the rapid development of new technologies for vaccine development and delivery. One key development has stemmed from the need for largescale production of ...

Although chimeric antigen receptor (CAR) T-cell therapies have shown encouraging results for treating hematological cancers such as leukemias and lymphomas, their success in solid tumors has so far ...

Partner Dan Shores will present a webinar titled "The mRNA/Lipid Nanoparticle Competitive and Litigation Landscape" for Medmarc, the leading expert in the products liability risks facing medical ...

Advances in sequencing technologies have accelerated the discovery of the genetic causation of diseases and new cell types. This revolution has also given rise to a new technique known as genetic ...